We design the model.
The ventures follow.
AI-accelerated. Platform-driven. Venture-minded.
QADR Biotechnology is a next-generation holding company developing science-led ventures, therapeutic concepts, and health brands through an AI-accelerated model of discovery, validation, and value creation.
We don't inherit a legacy.
We construct a method.
Biotechnology is entering a programmable era. The old model — fragmented, slow, artisanal — is being replaced by something faster, more precise, and more intelligent. QADR was designed for that transition.
Four ventures structured, IP-positioned, and market-defined within the QADR holding model from day one.
From signal to scale.
We identify emerging scientific opportunities before they become obvious.
We frame IP, scientific narrative, and strategic positioning.
AI compresses timelines across discovery, validation, and formulation.
We create ventures, platforms, and health brands with market logic.
We design assets for reproducibility and long-term value creation.
We identify emerging scientific opportunities before they become obvious.
We frame IP, scientific narrative, and strategic positioning.
AI compresses timelines across discovery, validation, and formulation.
We create ventures, platforms, and health brands with market logic.
We design assets for reproducibility and long-term value creation.
Built differently, by design.
We think from the next decade backward, not from yesterday forward.
AI is embedded in the engine: exploration, prioritization, formulation, execution.
We build reproducible systems, not isolated projects.
Building for the long horizon.
QADR is early-stage by timeline, future-stage by design.
GutRecover Therapeutics
Science-grounded gut health formulations at the intersection of microbiome research and recovery science.
→Stryō
Evidence-based performance and recovery — built for a market that demands more than a marketing claim.
→Muihā
Precision micronutrient support grounded in gut-metabolic science — daily ritual meets clinical evidence.
→Biomaē
Microbiome-informed wellness translating gut-body axis science into accessible, evidence-backed daily products.
→Designed for compounding.
Built for the long arc of biotech.
One holding model. Four ventures. Assets that build on each other over time.
Work with us.
We engage with scientists, investors, and partners building in the same direction.
The infrastructure we've built.
QADR is not defined by a single product or a single pipeline. It is defined by its system — a repeatable model for identifying, structuring, accelerating, and building high-impact biotech assets.
A system for building biotech, faster.
QADR operates as an AI-native holding structure. At the holding level, we identify scientific opportunities, frame IP strategy, and define venture architectures. At the venture level, we execute: scientific validation, product development, brand positioning, and market entry. AI is present at every layer — not as a marketing claim, but as a functional accelerant in research, formulation, prioritization, and execution.
Signal to scale, in detail.
We identify emerging scientific opportunities before they become obvious.
We scan adjacent spaces where emerging science, unmet need, and commercial opportunity intersect. We prioritize areas where AI can compress the distance between insight and asset.
We frame IP, narrative, and strategic positioning.
We architect the venture before we build it. IP positioning, scientific narrative, regulatory pathway, and market framing defined before significant capital deployment.
AI compresses timelines across discovery and formulation.
We use AI across discovery (literature synthesis, target identification), formulation (prediction and optimization), and execution (operational compression of timelines).
We create ventures with internal discipline and commercial logic.
We create ventures with defined milestones, brand architecture, commercial logic, and platform scalability from day one.
We design assets for reproducibility and long-term value.
Every asset we build is designed to compound — in evidence, in brand equity, in market position.
We scan adjacent spaces where emerging science, unmet need, and commercial opportunity intersect.
IP positioning, scientific narrative, regulatory pathway, and market framing defined before capital deployment.
AI across discovery, formulation prediction, and operational compression of timelines.
Defined milestones, brand architecture, commercial logic, and platform scalability from day one.
Every asset designed to compound — in evidence, brand equity, and market position.
What we bring to every venture.
Scientific Opportunity Identification
We map emerging scientific literature against market gaps and commercial timing — identifying opportunities before they reach mainstream awareness. This involves systematic analysis of preprint activity, patent landscapes, and regulatory movement in targeted spaces. The output is a validated opportunity thesis, not a hypothesis.
IP Architecture & Strategy
Intellectual property strategy is the first deliverable on every venture — not an afterthought. Before product development begins, we define the freedom-to-operate landscape, identify differentiation windows, and establish the IP architecture the venture will be built around. Every asset is defensible from day one.
AI-Accelerated Discovery
We deploy AI across the discovery phase to compress what traditionally takes months into structured weeks — applied to literature synthesis, ingredient and target identification, and opportunity scoring. AI functions as a force multiplier for scientific decision-making at the early stage where most biotech value is created or destroyed.
Venture Architecture & Structuring
Each venture is structured at founding with the rigor of a mature company: legal entity design, IP assignment, regulatory pathway mapping, and brand architecture — all defined before product development begins. This is the QADR model in practice: build the scaffold first, then execute with discipline.
Brand & Product Development
Brand development inside QADR starts with the science, not the aesthetic. Every brand is built outward from its scientific positioning — naming, visual identity, product architecture, and market narrative derived from the underlying evidence base. The result is brands that can defend their claims as rigorously as their market position.
Strategic Capital & Partnership Design
We structure capital and partnership arrangements matched to each asset's specific trajectory — whether scientific co-development, IP licensing, joint venture formation, or strategic investment. We prioritize long-term structural alignment over short-term convenience, consistent with a holding model designed for compounding value creation.
We partner with scientific founders, IP holders, and institutional partners.
Explore partnership opportunities →The portfolio in motion.
Four ventures. One holding model. Built to compound.
QADR currently operates four active ventures across therapeutic development, consumer health, and microbiome-informed wellness. Each was architected within the QADR holding model — structured IP, defined market positioning, and AI-accelerated execution from day one.
Therapeutic · Gut Health
GutRecover Therapeutics
Science-led therapeutics for gut health and recovery.
GutRecover Therapeutics is the primary operating entity of the QADR group, developing science-grounded formulations at the intersection of gut microbiome research and recovery science. The gut health market is one of the most evidence-rich segments in functional health — driven by growing clinical literature linking the gut-brain and gut-body axis to systemic health outcomes. GutRecover addresses this with formulations built around validated mechanisms, AI-accelerated ingredient selection, and brand architecture designed for both direct-to-consumer and professional channels. GutRecover Therapeutics LLC is incorporated in Delaware, USA.
GutRecover Therapeutics LLC · Delaware, USA
Learn more →Consumer Health · Performance & Recovery
Stryō
Performance and recovery, built with discipline.
Stryō is a direct-to-consumer performance and recovery brand built on evidence-grounded formulation logic, not convention. The performance supplement category is among the fastest-growing in consumer health — and one of the most underdifferentiated. Stryō's edge is its QADR-model origin: every formulation is designed around scientific evidence first, with brand architecture and market positioning built outward from that foundation. Stryō targets performance-conscious consumers who require more than a marketing claim.
stryo.store →Consumer Health · Precision Replenishment
Muihā
Precision health replenishment.
Muihā operates at the convergence of microbiome science and precision nutrition — a category where the clinical evidence base is maturing rapidly and consumer awareness is accelerating. The brand delivers targeted micronutrient and functional support grounded in gut-metabolic science, designed as a daily ritual rather than an episodic supplement. Muihā is positioned at the premium end of a market moving from generalist wellness toward science-backed precision health — a structural shift the QADR platform identified early.
muiha-replenisher.com →Microbiome · Wellness
Biomaē
Microbiome-informed wellness.
Biomaē is QADR's microbiome-focused consumer brand, translating the science of the gut-body axis into accessible daily wellness products. Developed through the QADR platform model — starting from scientific positioning and building brand architecture outward from evidence — Biomaē serves a rapidly growing consumer segment seeking microbiome-informed wellness grounded in clinical science rather than wellness trends.
microbiomae.shop →Building in the same space? We partner with scientific founders and IP-driven teams.
Explore partnerships →A new operating model for biotech.
We built QADR around a thesis: the traditional biotech model is too slow, too fragmented, and too dependent on legacy infrastructure. We designed something faster.
Biotech is entering a programmable era.
Traditional biotechnology operates in decades. Discovery to patient takes 10–15 years on average. The system is expensive, artisanal, and fragmented — each step performed by different actors with different incentives and no unified view of the whole.
AI changes this. Not by removing science — but by compressing the distance between scientific insight and structured asset. Faster literature synthesis. Better target identification. AI-assisted formulation and optimization. Smarter prioritization at every stage.
QADR was built for this transition. We don't wait for the industry to catch up. We operate with the tools and methods of the next era, applied today.
From signal to scale.
Identifying opportunity before it becomes obvious.
We scan adjacent spaces where emerging science, unmet need, and commercial opportunity intersect. We prioritize areas where AI can compress the distance between insight and asset.
Architecting the venture before building it.
IP positioning, scientific narrative, regulatory pathway, and market framing defined before significant capital deployment. We design the asset before we fund it.
AI as a functional accelerant at every layer.
We use AI across discovery (literature synthesis, target identification), formulation (prediction and optimization), and execution (operational compression of timelines).
Ventures with defined milestones and commercial logic.
Internal discipline at every stage: defined milestones, brand architecture, commercial logic, and platform scalability designed into the venture from day one.
Assets designed to compound over time.
Every asset we build is designed to compound — in evidence, in brand equity, in market position. Reproducibility is a design constraint, not an afterthought.
We scan adjacent spaces where emerging science, unmet need, and commercial opportunity intersect.
IP positioning, scientific narrative, regulatory pathway, and market framing defined before capital deployment.
AI across discovery, formulation prediction, and operational compression of timelines.
Defined milestones, brand architecture, commercial logic, and platform scalability from day one.
Every asset designed to compound — in evidence, brand equity, and market position.
Not a marketing claim.
An operating reality.
Literature synthesis, opportunity mapping, target identification — applied systematically across the portfolio. Applied to GutRecover Therapeutics, AI-assisted synthesis across hundreds of peer-reviewed publications on gut microbiome science identified high-signal ingredient targets and mapped their evidence base against safety and commercial viability — compressing a process that would take a research team months into a structured output in days.
AI-assisted ingredient optimization, efficacy prediction, and safety screening across therapeutic and consumer health products. In practice, formulation candidates are scored for ingredient compatibility, predicted efficacy, and regulatory risk before any lab work begins — eliminating low-probability compositions early and concentrating effort on high-confidence formulations. This shifts the bottleneck from discovery to validation.
Content generation, brand execution, and workflow automation across all ventures — reducing time from insight to market.
One platform. Four ventures.
One method.
QADR Biotechnology Holding SARLAU is the parent structure. It owns the IP, the brand architectures, and the operating methodology. Each venture operates with defined autonomy under the holding umbrella — sharing infrastructure, scientific resources, and AI tooling.
Interested in applying this model to your own scientific opportunity?
Contact us →Designed from day one for
the next era of biotech.
We started with the question,
not the answer.
QADR Biotechnology was founded on a simple but demanding thesis: that the next generation of valuable biotech assets will be built by teams who combine scientific rigor with AI-native execution and strategic discipline — not teams who inherit large infrastructure and move slowly inside it.
We are deliberately early-stage. We have chosen to build the method before scaling the portfolio, to design the holding structure before filling it with assets, and to establish the brand architecture before generating the revenue. We believe that the quality of how we build is what determines the quality of what we build.
QADR is a holding company, not a product company. It is an operating model, not a pipeline. It is a system designed to produce high-impact health ventures — and to do so faster, smarter, and with greater execution discipline than the traditional model allows.
A holding model built for international execution.
QADR Biotechnology Holding SARLAU
Casablanca, Morocco
Holding entity. Owns the IP, brand architectures, and operating methodology. Defines the venture model and manages portfolio-level strategy and AI infrastructure.
GutRecover Therapeutics LLC
Delaware, USA
Primary operating entity. Therapeutic development, DTC brands, and venture execution. The operational arm of the QADR portfolio.
Early by timeline.
Future by design.
We are a young company. We say this not defensively but precisely: we have been building the infrastructure — legal, scientific, operational, and AI — before building the revenue. We believe this is the right sequence. The ventures we launch from this foundation will carry its discipline.
"We don't inherit a legacy. We construct a method."
Holding structure established
QADR Biotechnology Holding SARLAU incorporated — Casablanca, Morocco
US operating entity incorporated
GutRecover Therapeutics LLC registered in Delaware — primary operational arm of the portfolio
Four-venture portfolio structured
GutRecover, Stryō, Muihā, and Biomaē — each IP-positioned and market-defined within the holding model
AI infrastructure deployed
AI tooling embedded across scientific discovery, formulation acceleration, and operational execution
Built by people who think in systems.
QADR is currently in a lean founding phase. Team information will be published as the company moves into its next stage of development.
If you're building in the same direction, we want to hear from you.
Contact us →Work with us.
We engage with scientists, investors, and strategic partners who are building in the same direction.
We partner with scientific founders, IP holders, and research teams with relevant assets in microbiome, gut health, and adjacent therapeutic areas.
Subject: Partnership
We engage with investors, family offices, and funds interested in early-stage AI-native biotech holdings with a portfolio approach.
Subject: Investor Relations
QADR Biotechnology Holding SARLAU
Casablanca, Morocco
Holding entity
GutRecover Therapeutics LLC
Delaware, USA
Primary operating entity
We respond to all relevant inquiries within 3 business days.
LinkedIn →